Fundamental analysis · SEC EDGAR · TTM through 30/06/2026
RXRX · Nasdaq · Healthcare
Fundamental quality
68
out of 100
Recursion Pharmaceuticals, Inc. is in full growth mode but not yet profitable: revenue is growing strongly (61.3% a year), but it doesn't translate into earnings yet. On fundamental quality it scores 68 out of 100, profiling it as a company of reasonable quality. Its weakest area is its profitability (ROE -56.7%). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Recursion Pharmaceuticals applies AI at industrial scale to discover drugs: it automates millions of experiments and trains models on them, backed by NVIDIA as partner and investor. It has no approved products yet: it's a bet on the platform.
Revenue growth: 61.3%
ROE: -56.7%
Net debt/EBITDA: 1.16x
Source: SEC EDGAR · TTM through 30/06/2026
The score combines growth, profitability and financial strength. Here its growth weighs in its favor, while its profitability drags it down the most.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 4 | -87 | -51 | -262 |
| 2021 | 10 | -186 | -198 | -284 |
| 2022 | 40 | -239 | -121 | -550 |
| 2023 | 45 | -328 | -300 | -390 |
| 2024 | 59 | -464 | -373 | -575 |
| 2025 | 75 | -645 | -378 | -734 |
Between 2020 and 2025, revenue went from $4M to $75M (+1785%) and net income went from -$87M to -$645M (-641%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the half-year ended June 30, 2026, versus the half-year ended June 30, 2025 (SEC filings):
Compared with the previous close (March 31, 2026), this is what moved in its accounts:
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
This company doesn't pay a dividend: it reinvests all its earnings back into the business.
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Recursion Pharmaceuticals, Inc. cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Recursion Pharmaceuticals, Inc. a good company to invest in?
In terms of business quality, Recursion Pharmaceuticals, Inc. scores 68 out of 100 in our analysis, placing it as a company of reasonable quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Does Recursion Pharmaceuticals, Inc. have a lot of debt?
Not particularly. Its net debt is 1.16 times its EBITDA, a low level.
Is Recursion Pharmaceuticals, Inc. growing?
Its revenue has grown 61.3% annualized in recent years, and without interruption since 2020.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Centene (CNC) · Labcorp (LH) · Quest Diagnostics (DGX) · Insulet (PODD) · Edwards Lifesciences (EW) · Molina Healthcare (MOH) · see more →
The best Healthcare stocks by our model →
Compare Recursion Pharmaceuticals, Inc. with 500+ companies in the screener →
Who's behind the methodology and model · how the score is computed
Data: see Recursion Pharmaceuticals, Inc.'s filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.